Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Spatial and temporal distribution of infectious disease epidemics, disasters and other potential public health emergencies in the World Health Organisation Africa region, 2016-2018.

Talisuna AO, Okiro EA, Yahaya AA, Stephen M, Bonkoungou B, Musa EO, Minkoulou EM, Okeibunor J, Impouma B, Djingarey HM, Yao NKM, Oka S, Yoti Z, Fall IS.

Global Health. 2020 Jan 15;16(1):9. doi: 10.1186/s12992-019-0540-4.

2.

Integrated Disease Surveillance and Response (IDSR) strategy: current status, challenges and perspectives for the future in Africa.

Fall IS, Rajatonirina S, Yahaya AA, Zabulon Y, Nsubuga P, Nanyunja M, Wamala J, Njuguna C, Lukoya CO, Alemu W, Kasolo FC, Talisuna AO.

BMJ Glob Health. 2019 Jul 3;4(4):e001427. doi: 10.1136/bmjgh-2019-001427. eCollection 2019. Review.

3.

Efficacy of Mobile Phone Short Message Service (SMS) Reminders on Malaria Treatment Adherence and Day 3 Post-Treatment Reviews (SMS-RES-MAL) in Kenya: A Study Protocol.

Talisuna AO, Zurovac D, Githinji S, Oburu A, Malinga J, Nyandigisi A, Jones CO, Snow RW.

J Clin Trials. 2019 Jun 25;5(2):217. doi: 10.4172/2167-0870.1000217. Epub 2015 Mar 23.

4.

Associations between IgG reactivity to Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) antigens and Burkitt lymphoma in Ghana and Uganda case-control studies.

Derkach A, Otim I, Pfeiffer RM, Onabajo OO, Legason ID, Nabalende H, Ogwang MD, Kerchan P, Talisuna AO, Ayers LW, Reynolds SJ, Nkrumah F, Neequaye J, Bhatia K, Theander TG, Prokunina-Olsson L, Turner L, Goedert JJ, Lavstsen T, Mbulaiteye SM.

EBioMedicine. 2019 Jan;39:358-368. doi: 10.1016/j.ebiom.2018.12.020. Epub 2018 Dec 20.

5.

A Cross-Sectional Population Study of Geographic, Age-Specific, and Household Risk Factors for Asymptomatic Plasmodium falciparum Malaria Infection in Western Kenya.

Peprah S, Tenge C, Genga IO, Mumia M, Were PA, Kuremu RT, Wekesa WN, Sumba PO, Kinyera T, Otim I, Legason ID, Biddle J, Reynolds SJ, Talisuna AO, Biggar RJ, Bhatia K, Goedert JJ, Pfeiffer RM, Mbulaiteye SM.

Am J Trop Med Hyg. 2019 Jan;100(1):54-65. doi: 10.4269/ajtmh.18-0481.

6.

A cross-sectional study of asymptomatic Plasmodium falciparum infection burden and risk factors in general population children in 12 villages in northern Uganda.

Maziarz M, Nabalende H, Otim I, Legason ID, Kinyera T, Ogwang MD, Talisuna AO, Reynolds SJ, Kerchan P, Bhatia K, Biggar RJ, Goedert JJ, Pfeiffer RM, Mbulaiteye SM.

Malar J. 2018 Jun 20;17(1):240. doi: 10.1186/s12936-018-2379-1.

7.

Developing a multisectoral National Action Plan for Health Security (NAPHS) to implement the International Health Regulations (IHR 2005) in Tanzania.

Mghamba JM, Talisuna AO, Suryantoro L, Saguti GE, Muita M, Bakari M, Rusibamayila N, Ally M, Bernard J, Banda R, Mapunda M, Eidex R, Sreedharan R, Sliter K, Nikkari S, Saikat S, Lolong GPM, Verboom P, Yahaya AA, Chungong S, Rodier G, Fall IS.

BMJ Glob Health. 2018 Mar 9;3(2):e000600. doi: 10.1136/bmjgh-2017-000600. eCollection 2018. Review.

8.

"We were being treated like the Queen": understanding trial factors influencing high paediatric malaria treatment adherence in western Kenya.

Jones C, Talisuna AO, Snow RW, Zurovac D.

Malar J. 2018 Jan 5;17(1):8. doi: 10.1186/s12936-017-2164-6.

9.

Intravenous artesunate plus Artemisnin based Combination Therapy (ACT) or intravenous quinine plus ACT for treatment of severe malaria in Ugandan children: a randomized controlled clinical trial.

Byakika-Kibwika P, Achan J, Lamorde M, Karera-Gonahasa C, Kiragga AN, Mayanja-Kizza H, Kiwanuka N, Nsobya S, Talisuna AO, Merry C.

BMC Infect Dis. 2017 Dec 28;17(1):794. doi: 10.1186/s12879-017-2924-5.

10.

Evaluating the Causal Link Between Malaria Infection and Endemic Burkitt Lymphoma in Northern Uganda: A Mendelian Randomization Study.

Legason ID, Pfeiffer RM, Udquim KI, Bergen AW, Gouveia MH, Kirimunda S, Otim I, Karlins E, Kerchan P, Nabalende H, Bayanjargal A, Emmanuel B, Kagwa P, Talisuna AO, Bhatia K, Yeager M, Biggar RJ, Ayers LW, Reynolds SJ, Goedert JJ, Ogwang MD, Fraumeni JF Jr, Prokunina-Olsson L, Mbulaiteye SM.

EBioMedicine. 2017 Nov;25:58-65. doi: 10.1016/j.ebiom.2017.09.037. Epub 2017 Oct 3.

11.

Age and geographic patterns of Plasmodium falciparum malaria infection in a representative sample of children living in Burkitt lymphoma-endemic areas of northern Uganda.

Maziarz M, Kinyera T, Otim I, Kagwa P, Nabalende H, Legason ID, Ogwang MD, Kirimunda S, Emmanuel B, Reynolds SJ, Kerchan P, Joloba MM, Bergen AW, Bhatia K, Talisuna AO, Biggar RJ, Goedert JJ, Pfeiffer RM, Mbulaiteye SM.

Malar J. 2017 Mar 20;16(1):124. doi: 10.1186/s12936-017-1778-z.

12.

Efficacy of text-message reminders on paediatric malaria treatment adherence and their post-treatment return to health facilities in Kenya: a randomized controlled trial.

Talisuna AO, Oburu A, Githinji S, Malinga J, Amboko B, Bejon P, Jones C, Snow RW, Zurovac D.

Malar J. 2017 Jan 25;16(1):46. doi: 10.1186/s12936-017-1702-6.

13.

Clinical determinants of early parasitological response to ACTs in African patients with uncomplicated falciparum malaria: a literature review and meta-analysis of individual patient data.

WWARN Artemisinin based Combination Therapy (ACT) Africa Baseline Study Group, Dahal P, d'Alessandro U, Dorsey G, Guerin PJ, Nsanzabana C, Price RN, Sibley CH, Stepniewska K, Talisuna AO.

BMC Med. 2015 Sep 7;13:212. doi: 10.1186/s12916-015-0445-x. Review.

14.

The past, present and future use of epidemiological intelligence to plan malaria vector control and parasite prevention in Uganda.

Talisuna AO, Noor AM, Okui AP, Snow RW.

Malar J. 2015 Apr 15;14:158. doi: 10.1186/s12936-015-0677-4. Review.

15.

The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data.

WorldWide Antimalarial Resistance Network (WWARN) AS-AQ Study Group, Adjuik MA, Allan R, Anvikar AR, Ashley EA, Ba MS, Barennes H, Barnes KI, Bassat Q, Baudin E, Björkman A, Bompart F, Bonnet M, Borrmann S, Brasseur P, Bukirwa H, Checchi F, Cot M, Dahal P, D'Alessandro U, Deloron P, Desai M, Diap G, Djimde AA, Dorsey G, Doumbo OK, Espié E, Etard JF, Fanello CI, Faucher JF, Faye B, Flegg JA, Gaye O, Gething PW, González R, Grandesso F, Guerin PJ, Guthmann JP, Hamour S, Hasugian AR, Hay SI, Humphreys GS, Jullien V, Juma E, Kamya MR, Karema C, Kiechel JR, Kremsner PG, Krishna S, Lameyre V, Ibrahim LM, Lee SJ, Lell B, Mårtensson A, Massougbodji A, Menan H, Ménard D, Menéndez C, Meremikwu M, Moreira C, Nabasumba C, Nambozi M, Ndiaye JL, Nikiema F, Nsanzabana C, Ntoumi F, Ogutu BR, Olliaro P, Osorio L, Ouédraogo JB, Penali LK, Pene M, Pinoges L, Piola P, Price RN, Roper C, Rosenthal PJ, Rwagacondo CE, Same-Ekobo A, Schramm B, Seck A, Sharma B, Sibley CH, Sinou V, Sirima SB, Smith JJ, Smithuis F, Somé FA, Sow D, Staedke SG, Stepniewska K, Swarthout TD, Sylla K, Talisuna AO, Tarning J, Taylor WR, Temu EA, Thwing JI, Tjitra E, Tine RC, Tinto H, Vaillant MT, Valecha N, Van den Broek I, White NJ, Yeka A, Zongo I.

BMC Med. 2015 Mar 31;13:66. doi: 10.1186/s12916-015-0301-z.

16.

Efficacy and safety of fixed-dose artesunate-amodiaquine vs. artemether-lumefantrine for repeated treatment of uncomplicated malaria in Ugandan children.

Yeka A, Lameyre V, Afizi K, Fredrick M, Lukwago R, Kamya MR, Talisuna AO.

PLoS One. 2014 Dec 1;9(12):e113311. doi: 10.1371/journal.pone.0113311. eCollection 2014.

17.

Paediatric pharmacovigilance: use of pharmacovigilance data mining algorithms for signal detection in a safety dataset of a paediatric clinical study conducted in seven African countries.

Kajungu DK, Erhart A, Talisuna AO, Bassat Q, Karema C, Nabasumba C, Nambozi M, Tinto H, Kremsner P, Meremikwu M, D'Alessandro U, Speybroeck N.

PLoS One. 2014 May 1;9(5):e96388. doi: 10.1371/journal.pone.0096388. eCollection 2014.

18.

Efficacy of quinine, artemether-lumefantrine and dihydroartemisinin-piperaquine as rescue treatment for uncomplicated malaria in Ugandan children.

Yeka A, Tibenderana J, Achan J, D'Alessandro U, Talisuna AO.

PLoS One. 2013;8(1):e53772. doi: 10.1371/journal.pone.0053772. Epub 2013 Jan 22.

19.

The Affordable Medicines Facility-malaria--a success in peril.

Talisuna AO, Adibaku S, Amojah CN, Amofah GK, Aubyn V, Dodoo A, Juma E, Jackou DH, Mkude S, Okui AP, Ramarosandratana B, Shija SJ.

Malar J. 2012 Nov 8;11:370. doi: 10.1186/1475-2875-11-370.

20.

Closing the access barrier for effective anti-malarials in the private sector in rural Uganda: consortium for ACT private sector subsidy (CAPSS) pilot study.

Talisuna AO, Daumerie PG, Balyeku A, Egan T, Piot B, Coghlan R, Lugand M, Bwire G, Rwakimari JB, Ndyomugyenyi R, Kato F, Byangire M, Kagwa P, Sebisubi F, Nahamya D, Bonabana A, Mpanga-Mukasa S, Buyungo P, Lukwago J, Batte A, Nakanwagi G, Tibenderana J, Nayer K, Reddy K, Dokwal N, Rugumambaju S, Kidde S, Banerji J, Jagoe G.

Malar J. 2012 Oct 29;11:356. doi: 10.1186/1475-2875-11-356.

21.

Mitigating the threat of artemisinin resistance in Africa: improvement of drug-resistance surveillance and response systems.

Talisuna AO, Karema C, Ogutu B, Juma E, Logedi J, Nyandigisi A, Mulenga M, Mbacham WF, Roper C, Guerin PJ, D'Alessandro U, Snow RW.

Lancet Infect Dis. 2012 Nov;12(11):888-96. doi: 10.1016/S1473-3099(12)70241-4. Review.

22.

Mobile phone text messaging: tool for malaria control in Africa.

Zurovac D, Talisuna AO, Snow RW.

PLoS Med. 2012 Feb;9(2):e1001176. doi: 10.1371/journal.pmed.1001176. Epub 2012 Feb 21. No abstract available.

23.

Antibodies reactive to Plasmodium falciparum serine repeat antigen in children with Burkitt lymphoma from Ghana.

Guech-Ongey M, Yagi M, Palacpac NM, Emmanuel B, Talisuna AO, Bhatia K, Stefan DC, Biggar RJ, Nkrumah F, Neequaye J, Tougan T, Horii T, Mbulaiteye SM.

Int J Cancer. 2012 Apr 15;130(8):1908-14. doi: 10.1002/ijc.26203. Epub 2011 Aug 8.

24.

Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria.

Achan J, Talisuna AO, Erhart A, Yeka A, Tibenderana JK, Baliraine FN, Rosenthal PJ, D'Alessandro U.

Malar J. 2011 May 24;10:144. doi: 10.1186/1475-2875-10-144. Review.

25.

Increasing malaria hospital admissions in Uganda between 1999 and 2009.

Okiro EA, Bitira D, Mbabazi G, Mpimbaza A, Alegana VA, Talisuna AO, Snow RW.

BMC Med. 2011 Apr 13;9:37. doi: 10.1186/1741-7015-9-37.

26.

Limited ability of Plasmodium falciparum pfcrt, pfmdr1, and pfnhe1 polymorphisms to predict quinine in vitro sensitivity or clinical effectiveness in Uganda.

Baliraine FN, Nsobya SL, Achan J, Tibenderana JK, Talisuna AO, Greenhouse B, Rosenthal PJ.

Antimicrob Agents Chemother. 2011 Feb;55(2):615-22. doi: 10.1128/AAC.00954-10. Epub 2010 Nov 15.

27.

Ebola hemorrhagic fever associated with novel virus strain, Uganda, 2007-2008.

Wamala JF, Lukwago L, Malimbo M, Nguku P, Yoti Z, Musenero M, Amone J, Mbabazi W, Nanyunja M, Zaramba S, Opio A, Lutwama JJ, Talisuna AO, Okware SI.

Emerg Infect Dis. 2010 Jul;16(7):1087-92. doi: 10.3201/eid1607.091525.

28.

African Burkitt's lymphoma: could collaboration with HIV-1 and malaria programmes reduce the high mortality rate?

Mbulaiteye SM, Talisuna AO, Ogwang MD, McKenzie FE, Ziegler JL, Parkin DM.

Lancet. 2010 May 8;375(9726):1661-3. doi: 10.1016/S0140-6736(10)60134-1. No abstract available.

PMID:
20452522
29.

Implementing Integrated Disease Surveillance and Response: Four African countries' experience, 1998-2005.

Nsubuga P, Brown WG, Groseclose SL, Ahadzie L, Talisuna AO, Mmbuji P, Tshimanga M, Midzi S, Wurapa F, Bazeyo W, Amri M, Trostle M, White M.

Glob Public Health. 2010;5(4):364-80. doi: 10.1080/17441690903334943.

PMID:
19916090
30.

Effectiveness of quinine versus artemether-lumefantrine for treating uncomplicated falciparum malaria in Ugandan children: randomised trial.

Achan J, Tibenderana JK, Kyabayinze D, Wabwire Mangen F, Kamya MR, Dorsey G, D'Alessandro U, Rosenthal PJ, Talisuna AO.

BMJ. 2009 Jul 21;339:b2763. doi: 10.1136/bmj.b2763.

31.

Quinine monotherapy for treating uncomplicated malaria in the era of artemisinin-based combination therapy: an appropriate public health policy?

Yeka A, Achan J, D'Alessandro U, Talisuna AO.

Lancet Infect Dis. 2009 Jul;9(7):448-52. doi: 10.1016/S1473-3099(09)70109-4. Review.

PMID:
19555904
32.

Pharmacovigilance of antimalarial treatment in Uganda: community perceptions and suggestions for reporting adverse events.

Bukirwa H, Nayiga S, Lubanga R, Mwebaza N, Chandler C, Hopkins H, Talisuna AO, Staedke SG.

Trop Med Int Health. 2008 Sep;13(9):1143-52. doi: 10.1111/j.1365-3156.2008.02119.x. Epub 2008 Jul 8.

33.

Monitoring antimalarial safety and tolerability in clinical trials: a case study from Uganda.

Staedke SG, Jagannathan P, Yeka A, Bukirwa H, Banek K, Maiteki-Sebuguzi C, Clark TD, Nzarubara B, Njama-Meya D, Mpimbaza A, Rosenthal PJ, Kamya MR, Wabwire-Mangen F, Dorsey G, Talisuna AO.

Malar J. 2008 Jun 11;7:107. doi: 10.1186/1475-2875-7-107.

34.

Safety and tolerability of combination antimalarial therapies for uncomplicated falciparum malaria in Ugandan children.

Maiteki-Sebuguzi C, Jagannathan P, Yau VM, Clark TD, Njama-Meya D, Nzarubara B, Talisuna AO, Kamya MR, Rosenthal PJ, Dorsey G, Staedke SG.

Malar J. 2008 Jun 11;7:106. doi: 10.1186/1475-2875-7-106.

35.

Intensity of malaria transmission and the spread of Plasmodium falciparum resistant malaria: a review of epidemiologic field evidence.

Talisuna AO, Okello PE, Erhart A, Coosemans M, D'Alessandro U.

Am J Trop Med Hyg. 2007 Dec;77(6 Suppl):170-80. Review.

PMID:
18165490
36.

Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial.

Kamya MR, Yeka A, Bukirwa H, Lugemwa M, Rwakimari JB, Staedke SG, Talisuna AO, Greenhouse B, Nosten F, Rosenthal PJ, Wabwire-Mangen F, Dorsey G.

PLoS Clin Trials. 2007 May 18;2(5):e20.

37.

Diagnosis and treatment of malaria.

Talisuna AO, Meya DN.

BMJ. 2007 Feb 24;334(7590):375-6. No abstract available.

38.
39.

Pharmacovigilance of antimalarial treatment in Africa: is it possible?

Talisuna AO, Staedke SG, D'Alessandro U.

Malar J. 2006 Jun 16;5:50.

40.

Manslaughter by fake artesunate in Asia--will Africa be next?

Newton PN, McGready R, Fernandez F, Green MD, Sunjio M, Bruneton C, Phanouvong S, Millet P, Whitty CJ, Talisuna AO, Proux S, Christophel EM, Malenga G, Singhasivanon P, Bojang K, Kaur H, Palmer K, Day NP, Greenwood BM, Nosten F, White NJ.

PLoS Med. 2006 Jun;3(6):e197. No abstract available.

41.

Malaria transmission intensity and the rate of spread of chloroquine resistant Plasmodium falciparum: Why have theoretical models generated conflicting results?

Talisuna AO, Erhart A, Samarasinghe S, Van Overmeir C, Speybroeck N, D'Alessandro U.

Infect Genet Evol. 2006 May;6(3):241-8. Epub 2005 Aug 22.

PMID:
16112915
42.

Research on stored biological samples: the views of Ugandans.

Wendler D, Pace C, Talisuna AO, Maiso F, Grady C, Emanuel E.

IRB. 2005 Mar-Apr;27(2):1-5. No abstract available.

PMID:
15948324
43.

Two mutations in dihydrofolate reductase combined with one in the dihydropteroate synthase gene predict sulphadoxine-pyrimethamine parasitological failure in Ugandan children with uncomplicated falciparum malaria.

Talisuna AO, Nalunkuma-Kazibwe A, Langi P, Mutabingwa TK, Watkins WW, Van Marck E, Egwang TG, D'Alessandro U.

Infect Genet Evol. 2004 Dec;4(4):321-7.

PMID:
15374529
44.

Population-based validation of dihydrofolate reductase gene mutations for the prediction of sulfadoxine-pyrimethamine resistance in Uganda.

Talisuna AO, Langi P, Mutabingwa TK, Watkins W, Van Marck E, Egwang TG, D'Alessandro U.

Trans R Soc Trop Med Hyg. 2003 May-Jun;97(3):338-42.

PMID:
15228255
45.

Efficacy of sulphadoxine-pyrimethamine alone or combined with amodiaquine or chloroquine for the treatment of uncomplicated falciparum malaria in Ugandan children.

Talisuna AO, Nalunkuma-Kazibwe A, Bakyaita N, Langi P, Mutabingwa TK, Watkins WW, Van Marck E, D'Alessandro U, Egwang TG.

Trop Med Int Health. 2004 Feb;9(2):222-9.

46.

History, dynamics, and public health importance of malaria parasite resistance.

Talisuna AO, Bloland P, D'Alessandro U.

Clin Microbiol Rev. 2004 Jan;17(1):235-54. Review.

47.

Pathogen genotyping in polyclonal infections: application of a fluorogenic polymerase-chain-reaction assay in malaria.

Decuypere S, Elinck E, Van Overmeir C, Talisuna AO, D'Alessandro U, Dujardin JC.

J Infect Dis. 2003 Oct 15;188(8):1245-9. Epub 2003 Oct 6.

PMID:
14551896
48.

Intensity of transmission and spread of gene mutations linked to chloroquine and sulphadoxine-pyrimethamine resistance in falciparum malaria.

Talisuna AO, Langi P, Mutabingwa TK, Van Marck E, Speybroeck N, Egwang TG, Watkins WW, Hastings IM, D'Alessandro U.

Int J Parasitol. 2003 Sep 15;33(10):1051-8.

PMID:
13129527
49.

Role of the pfcrt codon 76 mutation as a molecular marker for population-based surveillance of chloroquine (CQ)-resistant Plasmodium falciparum malaria in Ugandan sentinel sites with high CQ resistance.

Talisuna AO, Kyosiimire-Lugemwa J, Langi P, Mutabingwa TK, Watkins W, Van Marck E, Egwang T, D'Alessandro U.

Trans R Soc Trop Med Hyg. 2002 Sep-Oct;96(5):551-6.

PMID:
12474488
50.

Increasing antimalarial drug resistance in Uganda and revision of the national drug policy.

Kamya MR, Bakyaita NN, Talisuna AO, Were WM, Staedke SG.

Trop Med Int Health. 2002 Dec;7(12):1031-41.

Supplemental Content

Loading ...
Support Center